A new section of the Journal of Translational Medicine is being introduced to encourage rapid communication of methods and results that utilize computational modeling and epidemiologic approaches in translational medicine. The focus will be on population-based studies that extend towards more molecular level analysis. Submission of studies involving methods development is encouraged where actual application and results can be shown in the healthcare and life sciences domains.
Editorial
We introduce a new section of the Journal of Translational Medicine to encourage rapid communication of methods and results that utilize computational modeling and epidemiologic approaches in translational medicine. The focus will be on population-based studies that extend towards more molecular level analysis. Submission of studies involving methods development is encouraged where actual application and results can be shown in the healthcare and life sciences domains.
We acknowledge the "flood of data" emanating from new technologies, e.g. genomic sequencing, but we must also consider the enormity of data already existing in clinical histories and observational studies, nationally and internationally. There remains a critical need to re-focus translational medicine on the clinical perspective, starting with clinical need, to enhance the value of molecularbased approaches. Both perspectives fundamentally drive clinical utility and are very complementary and have been discussed in editorials in this journal [1, 2] .
Ultimately translational medicine must improve patient care and enhance patient-physician communication and decision-making. Patients are complex biological systems (processes) that evolve over time under the influence of many factors, e.g. environmental, lifestyle, etc. that cause an individual's genomic risk to progress to disease. It is critical to understand, represent, analyze and interpret patients and disease, temporally, to acknowledge the complexity of disease presentation, diagnosis and treatment that go beyond genomic make-up. The successful integration of a more clinical/epidemiological base and one using high throughput technology to develop high resolution, but static, representation of a patient's state is critical in personalized and stratified medicine.
Genomic sequencing and gene expression analysis appear yield "quantitative" data for the bioinformatics community with little experience addressing clinical or epidemiologic data. These last two are viewed as "softer" or more "qualitative" but the reality of translational medicine can only succeed these data sources approach a continuum rather than separable silos. Accurate diagnosis of a patient is required to address stratification, disease subtyping, reliability of diagnostic criteria, physician compliance with guidelines and different EHR's and can limit the correlation of molecular observation with clinical manifestation. Extending this correlation towards critical mechanistic understanding would become impossible. Medical informatics has focused on immediate patient management and does not necessarily address the comprehensive data collection and data models necessary to support molecular studies and analysis.
Approaches to be highlighted in this section include: Clinical observations and patient history can provide temporal portraits of disease that complement genomic identification of risk and lead to improved patient management [11] . 10. Qualifying Data Content and quality: Important data sources exist containing lifestyle and socio cultural environment data, e.g. eating habits, socioeconomic situation, legal substance (tobacco, alcohol and psychoactive drugs) use and illegal substance use. These data sources include surveys.
Other important data may be Air Pollution Data Sources, i.e. air quality data [12] .
Submitted articles should describe how the approach and results reflect the computational modeling and epidemiologic aspects of translational medicine derived both from the richness of the data available (or to be developed), and from the versatility of analysis methodologies, to contextually answer to the needs in:
prevention (identification and evaluation of modifiable risk factors) diagnosis (optimization of early detection, stratification and staging) therapy (stratification of disease and personalization of treatment) health offer planning (optimization of service offerings based on volumes and health profiles of the population) compliance (to clinical practice guidelines, to patient behavior, to following physician orders) personalization (disease stratification based on clinical presentation) patient management (integration of patient stratification, e.g. genomics, disease stratification and therapeutic options/outcomes) forecasts (predictive models for patient subgroups for use in prevention, behavior modification, cost estimation, etc.) public policy (relationship between policies and public/patient/physician response; evidence for opportunities to impact policy development)
